How does OncuraKit's accuracy compare to traditional single-cancer screening tests?

Comparative accuracy: Colonoscopy for colorectal cancer: ~95% sensitivity but requires bowel prep, sedation, clinic visit, and has a ~0.5% serious complication rate. Mammography: 80–87% sensitivity for breast cancer (lower in dense breast tissue) with ~50% cumulative false-positive rate over 10 annual screenings. PSA: ~70–80% sensitivity for prostate cancer but ~70–80% false-positive rate leading to unnecessary biopsies. Low-dose CT for lung cancer: 94% sensitivity but 96% of positive findings are false positives (benign nodules). OncuraKit: 81–97% per-marker sensitivity at Stage I/II, >99.9% specificity with two-test confirmation, urine-only, no false positive imaging findings. OncuraKit is most comparable to LDCT in sensitivity, but with dramatically better specificity and much lower procedural burden.